203 related articles for article (PubMed ID: 15643450)
1. Effects of androgen suppression and radiation on prostate cancer suggest a role for angiogenesis blockade.
Woodward WA; Wachsberger P; Burd R; Dicker AP
Prostate Cancer Prostatic Dis; 2005; 8(2):127-32. PubMed ID: 15643450
[TBL] [Abstract][Full Text] [Related]
2. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Zhang M; Latham DE; Delaney MA; Chakravarti A
Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
[TBL] [Abstract][Full Text] [Related]
3. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
4. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
5. [Indications of the association of radiotherapy and hormonal treatment in prostate cancer].
Bolla M; Maingon P; Fourneret P; Artignan X; Descotes JL
Cancer Radiother; 2005 Nov; 9(6-7):394-8. PubMed ID: 16226044
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF).
Ling MT; Lau TC; Zhou C; Chua CW; Kwok WK; Wang Q; Wang X; Wong YC
Carcinogenesis; 2005 Oct; 26(10):1668-76. PubMed ID: 15905202
[TBL] [Abstract][Full Text] [Related]
7. Medical therapy of prostate cancer: 1999.
Afrin LB; Ergul SM
J S C Med Assoc; 2000 Feb; 96(2):77-84. PubMed ID: 10710906
[TBL] [Abstract][Full Text] [Related]
8. Low and intermediate risk prostate cancer-- role of hormonal therapy with external beam radiation therapy.
Martin J; Bristow R; Warde P
Can J Urol; 2006 Apr; 13 Suppl 2():63-7. PubMed ID: 16672132
[TBL] [Abstract][Full Text] [Related]
9. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones.
Guo Y; Wang S; Hoot DR; Clinton SK
J Nutr Biochem; 2007 Jun; 18(6):408-17. PubMed ID: 17142033
[TBL] [Abstract][Full Text] [Related]
10. The role of angiogenesis in prostate development and the pathogenesis of prostate cancer.
Hrouda D; Nicol DL; Gardiner RA
Urol Res; 2003 Feb; 30(6):347-55. PubMed ID: 12599013
[TBL] [Abstract][Full Text] [Related]
11. Radiation therapy combined with hormone therapy for prostate cancer.
Lee AK
Semin Radiat Oncol; 2006 Jan; 16(1):20-8. PubMed ID: 16378903
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis of prostate cancer and antiangiogenic therapy.
Uehara H
J Med Invest; 2003 Aug; 50(3-4):146-53. PubMed ID: 13678383
[TBL] [Abstract][Full Text] [Related]
13. Novel secondary hormonal therapy in advanced prostate cancer: an update.
Van Allen EM; Ryan CJ
Curr Opin Urol; 2009 May; 19(3):315-21. PubMed ID: 19342958
[TBL] [Abstract][Full Text] [Related]
14. Duration of testosterone suppression and the risk of death from prostate cancer in men treated with radiation and 6 months of hormone therapy.
Palma D; Pickles T
Cancer; 2008 May; 112(10):2322-3; author reply 2323. PubMed ID: 18327816
[No Abstract] [Full Text] [Related]
15. The benefits of early androgen blockade.
Maroni PD; Crawford ED
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):317-29. PubMed ID: 18471789
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells.
Yano A; Fujii Y; Iwai A; Kageyama Y; Kihara K
Clin Cancer Res; 2006 May; 12(10):3003-9. PubMed ID: 16707595
[TBL] [Abstract][Full Text] [Related]
17. Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate.
Colombel M; Filleur S; Fournier P; Merle C; Guglielmi J; Courtin A; Degeorges A; Serre CM; Bouvier R; Clézardin P; Cabon F
Cancer Res; 2005 Jan; 65(1):300-8. PubMed ID: 15665307
[TBL] [Abstract][Full Text] [Related]
18. Antiandrogens in the treatment of prostate cancer.
Wirth MP; Hakenberg OW; Froehner M
Eur Urol; 2007 Feb; 51(2):306-13; discussion 314. PubMed ID: 17007995
[TBL] [Abstract][Full Text] [Related]
19. Current status and prospects of androgen depletion therapy for prostate cancer.
Akaza H
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):293-302. PubMed ID: 18471787
[TBL] [Abstract][Full Text] [Related]
20. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]